文献速递血脂与心血管预防

PCSK9缺陷减少胰岛素分泌并促发葡萄糖不耐受:低密度脂蛋白受体的作用

PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
PubMed 文献 · Eur Heart J · 2019-01-01

该研究利用Pcsk9敲除、Ldlr敲除及双敲除等多种小鼠模型,探讨PCSK9功能缺失导致高血糖和2型糖尿病风险的分子机制。结果显示Pcsk9敲除小鼠葡萄糖清除受损但胰岛素敏感性正常,胰腺胰岛增大伴胆固醇酯堆积、血浆胰岛素和C肽降低,该表型在Pcsk9/Ldlr双敲除及肝脏选择性Pcsk9敲除小鼠中完全逆转。结论提示局部产生的PCSK9通过调控胰腺LDLR影响β细胞功能,而循环PCSK9不参与此过程。

要点

  • PCSK9缺陷小鼠葡萄糖清除受损,但胰岛素敏感性未受影响。
  • 胰岛增大伴胆固醇酯堆积、血浆胰岛素和C肽降低。
  • 肝脏选择性敲除Pcsk9不影响β细胞功能,提示局部PCSK9作用。

核心结论

  • PCSK9通过调控胰腺LDLR表达限制β细胞胆固醇过载,维持胰岛素分泌平衡。
  • 该效应独立于循环PCSK9,可能与局部产生的PCSK9相关。

研究设计与样本

  • 使用Pcsk9 KO、WT、Pcsk9/Ldlr双KO、Ldlr KO、肝脏选择性Pcsk9 KO(AlbCre+/Pcsk9LoxP/LoxP)及对照小鼠。
  • 进行GTT、ITT、血浆胰岛素和C肽检测、胰腺形态学及胰岛胆固醇积累分析。
  • 标准饮食或高脂饮食喂养20周。

主要发现

  • Pcsk9 KO小鼠标准或高脂饮食20周后葡萄糖清除较WT显著受损,胰岛素敏感性未受影响。
  • Pcsk9 KO小鼠胰岛增大,胆固醇酯积累增加,细胞内胰岛素水平升高而血浆胰岛素和C肽降低。
  • Pcsk9/Ldlr双KO小鼠表型完全逆转,提示LDLR介导该效应。
  • 肝脏选择性Pcsk9 KO小鼠(缺乏可检测的循环PCSK9)表型完全恢复。

临床怎么用

  • PCSK9抑制剂主要靶向循环PCSK9,本研究提示循环PCSK9不影响β细胞功能,支持其血糖安全性。

局限性

  • 研究基于动物模型,人体中的相关性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: PCSK9 loss of function genetic variants are associated with lower low-density lipoprotein cholesterol but also with higher plasma glucose levels and increased risk of Type 2 diabetes mellitus. Here, we investigated the molecular mechanisms underlying this association. METHODS AND RESULTS: Pcsk9 KO, WT, Pcsk9/Ldlr double KO (DKO), Ldlr KO, albumin AlbCre+/Pcsk9LoxP/LoxP (liver-selective Pcsk9 knock-out mice), and AlbCre-/Pcsk9LoxP/LoxP mice were used. GTT, ITT, insulin and C-peptide plasma levels, pancreas morphology, and cholesterol accumulation in pancreatic islets were studied in the different animal models. Glucose clearance was significantly impaired in Pcsk9 KO mice fed with a standard or a high-fat diet for 20 weeks compared with WT animals; insulin sensitivity, however, was not affected. A detailed analysis of pancreas morphology of Pcsk9 KO mice vs. controls revealed larger islets with increased accumulation of cholesteryl esters, paralleled by increased insulin intracellular levels and decreased plasma insulin, and C-peptide levels. This phenotype was completely reverted in Pcsk9/Ldlr DKO mice implying the low-density lipoprotein receptor (LDLR) as the proprotein convertase subtilisin/kexin Type 9 (PCSK9) target responsible for the phenotype observed. Further studies in albumin AlbCre+/Pcsk9LoxP/LoxP mice, which lack detectable circulating PCSK9, also showed a complete recovery of the phenotype, thus indicating that circulating, liver-derived PCSK9, the principal target of monoclonal antibodies, does not impact beta-cell function and insulin secretion. CONCLUSION: PCSK9 critically controls LDLR expression in pancreas perhaps contributing to the maintenance of a proper physiological balance to limit cholesterol overload in beta cells. This effect is independent of circulating PCSK9 and is probably related to locally produced PCSK9.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Da Dalt L, Ruscica M, Bonacina F, et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J. 2019. PMID: 29982592. doi:10.1093/eurheartj/ehy357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。